On March 31, 2026, SCYNEXIS, Inc. held a conference call to discuss its recent asset acquisition transaction and provide a corporate update. The call highlighted the company's strategic focus on advancing innovative solutions for severe rare diseases, particularly in the area of Autosomal Dominant Polycystic Kidney Disease (ADPKD). During the call, SCYNEXIS presented a corporate deck that detailed the clinical development of its product candidates, including SCY-770 and SCY-247, which are aimed at addressing significant unmet medical needs in the ADPKD market. The company reported a successful $40 million financing round, which is expected to extend its cash runway into mid-2029. This financing will support the ongoing development of SCY-770, an AMPK activator that has shown promise in preclinical studies for treating ADPKD. The company also discussed its partnership with GlaxoSmithKline regarding BREXAFEMME, which has the potential to deliver significant sales milestones and royalties. The information shared during the call is intended to provide investors with a clearer understanding of SCYNEXIS's strategic direction and operational execution as it seeks to enhance shareholder value through innovative therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.